ACLX Arcellx
- 51.920
- +0.540+1.05%
- 51.920
- 0.0000.00%
Arcellx News
Should You Be Bullish on Arcellx (ACLX)?
Arcellx(ACLX.US) Director Sells US$522.26K in Common Stock
$Arcellx(ACLX.US)$ Director Ware Olivia C sold 9,402 shares of common stock on Apr 16, 2024 at an average price of $55.5477 for a total value of $522.26K.Source: Announcement What is statement of chan
Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing
Olivia C Ware, Director, on April 16, 2024, sold 9,402 shares in Arcellx (ACLX) for $522,260. SEC Filing: https://www.sec.gov/Archives/edgar/data/1786205/000141588924011120/xslF345X03/form4-04182024_0
Peering Into Arcellx's Recent Short Interest
Arcellx's (NYSE:ACLX) short percent of float has risen 6.28% since its last report. The company recently reported that it has 3.77 million shares sold short, which is 8.12% of all regular shares that
Buy Rating Backed by Potential Regulatory Tailwinds for Arcellx's CAR-T Therapy
Express News | Needham Reiterates Buy on Arcellx, Maintains $81 Price Target
Arcellx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/11/2024 37.1% Needham → $81 Reiterates Buy → Buy 03/18/2024 37.1% Needham $72 → $81 Maintains Buy 03/14
Optimizing Investment Decisions: Unveiling the Buy Rating for Arcellx Inc.
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)
Arcellx(ACLX.US) Officer Sells US$1.55 Million in Common Stock
$Arcellx(ACLX.US)$ Officer Elghandour Rami sold 23,086 shares of Common Stock on Apr 1, 2024 at an average price of $67.092 for a total value of $1.55 million.Source: Announcement What is statement of
Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing
Rami Elghandour, Director, President, CEO and Chairman of the Board, on April 01, 2024, sold 23,086 shares in Arcellx (ACLX) for $1,548,887. Following the Form 4 filing with the SEC, Elghandour has co
Form 144 | Arcellx(ACLX.US) Officer Proposes to Sell 1.61 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Arcellx(ACLX.US)$ Officer RAMI ELGHANDOUR intends to sell 23,086 shares of its common stock on Apr 1, with a total market value of approximately $1.61 million. RAMI E
13D Filings -- Barron's
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
Insiders Are Dumping These 10 Healthcare Stocks
Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares
Arcellx(ACLX.US) Officer Sells US$3.28 Million in Common Stocks
$Arcellx(ACLX.US)$ Officer Heery Christopher sold 46,815 shares of Common Stocks on Mar 22, 26, 2024 at an average price of $70.0569 for a total value of $3.28 million.Source: Announcement What is sta
Arcellx Insider Sold Shares Worth $35,575,755, According to a Recent SEC Filing
Jill Carroll, Director, on March 21, 2024, sold 504,263 shares in Arcellx (ACLX) for $35,575,755. Following the Form 4 filing with the SEC, Carroll has control over a total of 1,479,148 shares of the
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management
Analysis
Price Target
No Data
